Acadia's Nuplazid Could Have The Alzheimer's R&D Curse

Acadia's Nuplazid (pimavanserin) has met its primary endpoint in a Phase II study in patients with Alzheimer’s disease psychosis – but a secondary endpoint miss in the same study has triggered alarm bells for future development of the product in Alzheimer's, a historically risky scene, marred by many Phase III failures.